XFOR250117C1000
- 0.20
- +0.10+100.00%
X4 Pharmaceuticals Newsroom
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 99% Over Last Week
X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition
Express News | X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
B.Riley Financial Maintains X4 Pharmaceuticals(XFOR.US) With Hold Rating, Cuts Target Price to $0.5
B. Riley Adjusts X4 Pharmaceuticals Price Target to $0.50 From $1, Maintains Neutral Rating
Express News | HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $1.5
X4 Pharmaceuticals Is Maintained at Buy by Stifel
X4 Pharmaceuticals Analyst Ratings
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript Summary
X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript
10-Q: Q3 2024 Earnings Report
X4 Pharmaceuticals: Promising Phase 2 Trial Results
X4 Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results.
Express News | X4 Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results
8-K: X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | X4 Pharmaceuticals: Co Had $135.8 Mln in Cash, Cash Equivalents, Restricted Cash, & Short-Term Marketable Securities as of Sept 30, 2024
X4 Pharmaceuticals Reports Q3 EPS (18c), Consensus (17c)
Press Release: X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update